Ctd Holdings Inc (CTDH) 0.3600 $CTDH
CTD Holdings Closes on $2 Million Private Placement
Marketwired - Tue Jun 07, 6:00AM CDT
William S. Shanahan, Former President of Colgate-Palmolive, Joins the Company's Board of Directors
CTD Holdings to Present "Management of Niemann-Pick Type C With Intravenous Hydroxypropyl- b -Cyclodextrin" at Ara Parseghian Medical Research Foundation Annual Conference
Marketwired - Tue May 03, 9:48AM CDT
CTD Holdings (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will present its findings on the intravenous treatment of Niemann-Pick Type C (NPC) patients at the annual conference of the Ara Parseghian Medical Research Foundation in Tucson, Arizona, June 4-7, 2016.
Global Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Pipeline Review 2015
M2 - Fri Jan 22, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8n22q/acid) has announced the addition of the "Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Overview - Therapeutics Development - Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Overview - Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Comparative Analysis - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics under Development by Companies - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics under Investigation by Universities/Institutes - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Products under Development by Companies - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Products under Investigation by Universities/Institutes - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Companies Involved in Therapeutics Development - CTD Holdings, Inc. - La Jolla Pharmaceutical Company - Merck & Co., Inc. - Okklo Life Sciences BV - Orphazyme ApS For more information visit http://www.researchandmarkets.com/research/h8n22q/acid
MRK: 57.18 (-0.44)
CTD Holdings plans divestiture of fine chemical unit to focus on biopharmaceutical business
M2 - Thu Jan 14, 5:57AM CST
Biotechnology company CTD Holdings (Other OTC:CTDH) said on Wednesday that it proposes to divest its specialty fine chemical business to focus exclusively on drug development.
CTD Holdings Enters Into Letter of Intent to Sell Fine Chemical Unit
Marketwire Canada - Wed Jan 13, 6:24AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based biopharmaceuticals for the treatment of disease, today announced that it plans to sell its specialty fine chemical business in order to focus exclusively on drug development.
CTD Holdings' Clinical Trial Design Receives Positive Responses From U.K.'s Medicines and Healthcare Products Regulatory Agency
Marketwired - Mon Dec 14, 6:00AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, has received positive responses from a major U.K. healthcare regulator to the clinical trial design for its Trappsol® Cyclo(TM) drug, which is used to treat Niemann-Pick Type C (NPC). NPC is a rare and fatal cholesterol metabolism disease found primarily in children and young adults.
CTD Holdings names Judge Joseph J. Farnan to board
M2 - Thu Nov 05, 4:28AM CST
Biotechnology company CTD Holdings (Other OTC:CTDH) revealed on Wednesday that it has appointed Judge Joseph J. Farnan to its board of directors.
Joseph J. Farnan, Jr. Joins CTD Holdings Board of Directors
Marketwired - Wed Nov 04, 11:31AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that Judge Joseph J. Farnan of the Wilmington, Delaware law firm, Farnan LLP, has joined its Board of Directors.
CTD Holdings appoints two new co-chairs to SAB
M2 - Tue Oct 27, 5:08AM CDT
Biotechnology company CTD Holdings (Other OTC:CTDH) disclosed on Monday that it has appointed Dr Rita Colwell and Dr Sharon Hrynkow as co chairs of its Scientific Advisory Board (SAB).
CTD Holdings Names Dr. Rita Colwell and Dr. Sharon Hrynkow Co-Chairs of Scientific Advisory Board
Marketwired - Mon Oct 26, 11:40AM CDT
CTD Holdings, Inc. (OTCQB: CTDH) today announced Dr. Rita Colwell, Distinguished University Professor, University of Maryland at College Park and Johns Hopkins University Bloomberg School of Public Health, has joined their Scientific Advisory Board (SAB) and will co-chair the SAB with Dr. Sharon Hrynkow, Senior Vice President for Medical Affairs, CTD.
N. Scott Fine Named CEO of CTD Holdings
Marketwired - Wed Sep 16, 2:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that the Board of Directors has named N. Scott Fine as Chief Executive Officer. Mr. Fine, who was previously Chairman of the Board and Lead Director, will continue as Chairman. Director Markus W. Sieger was named Lead Director, and Senior Medical Advisor Dr. Sharon H. Hrynkow joins the company as Senior Vice President for Medical Affairs.
CTD Holdings to Present at UK Annual Conference for NPC Patients, Families and Caregivers
Marketwired - Thu Sep 03, 6:00AM CDT
September 3, 2015 - CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, will make a formal presentation on progress in its clinical trials program on September 19 at a major annual meeting of caregivers and families struggling with Niemann-Pick Type C (NPC) disease. The meeting will be convened in Bedfordshire, England, under the auspices of the Niemann-Pick UK, a registered charity in the United Kingdom. The annual meeting brings together experts from around the world for interactive sessions on clinical and practical management of NPC, and on clinical trials aimed at slowing the progression of the disease. The company's formal presentation will be held on Saturday, September 19.
CTD Holdings announces private placement of 1.3m shares of its common stock
M2 - Tue Sep 01, 10:45AM CDT
Biotechnology company CTD Holdings (Other OTC:CTDH) said on Monday that it has completed the sale of 1,300,000 shares of its common stock at a price per share of USD0.50 in a private placement.
CTD Holdings Sets Meeting With European Health Authority on Clinical Development Plans
Marketwired - Mon Aug 24, 6:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that is developing Trappsol® Cyclo(TM) as a treatment for Niemann-Pick Type C (NPC) disease, today announced that the company has set a meeting with a European health authority to discuss its initial clinical development plans. These plans have been based upon extensive discussions with clinical experts, some of whom have more than five years of experience from the compassionate use of Trappsol® Cyclo(TM) in the management of NPC patients.
CTD Holdings Closes on $2 Million Private Placement
Marketwired - Tue Jun 07, 6:00AM CDT
William S. Shanahan, Former President of Colgate-Palmolive, Joins the Company's Board of Directors
CTD Holdings to Present "Management of Niemann-Pick Type C With Intravenous Hydroxypropyl- b -Cyclodextrin" at Ara Parseghian Medical Research Foundation Annual Conference
Marketwired - Tue May 03, 9:48AM CDT
CTD Holdings (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will present its findings on the intravenous treatment of Niemann-Pick Type C (NPC) patients at the annual conference of the Ara Parseghian Medical Research Foundation in Tucson, Arizona, June 4-7, 2016.
Global Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Pipeline Review 2015
M2 - Fri Jan 22, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8n22q/acid) has announced the addition of the "Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Overview - Therapeutics Development - Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Overview - Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Comparative Analysis - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics under Development by Companies - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics under Investigation by Universities/Institutes - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Products under Development by Companies - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Products under Investigation by Universities/Institutes - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Companies Involved in Therapeutics Development - CTD Holdings, Inc. - La Jolla Pharmaceutical Company - Merck & Co., Inc. - Okklo Life Sciences BV - Orphazyme ApS For more information visit http://www.researchandmarkets.com/research/h8n22q/acid
MRK: 57.18 (-0.44)
CTD Holdings plans divestiture of fine chemical unit to focus on biopharmaceutical business
M2 - Thu Jan 14, 5:57AM CST
Biotechnology company CTD Holdings (Other OTC:CTDH) said on Wednesday that it proposes to divest its specialty fine chemical business to focus exclusively on drug development.
CTD Holdings Enters Into Letter of Intent to Sell Fine Chemical Unit
Marketwire Canada - Wed Jan 13, 6:24AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based biopharmaceuticals for the treatment of disease, today announced that it plans to sell its specialty fine chemical business in order to focus exclusively on drug development.
CTD Holdings' Clinical Trial Design Receives Positive Responses From U.K.'s Medicines and Healthcare Products Regulatory Agency
Marketwired - Mon Dec 14, 6:00AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, has received positive responses from a major U.K. healthcare regulator to the clinical trial design for its Trappsol® Cyclo(TM) drug, which is used to treat Niemann-Pick Type C (NPC). NPC is a rare and fatal cholesterol metabolism disease found primarily in children and young adults.
CTD Holdings names Judge Joseph J. Farnan to board
M2 - Thu Nov 05, 4:28AM CST
Biotechnology company CTD Holdings (Other OTC:CTDH) revealed on Wednesday that it has appointed Judge Joseph J. Farnan to its board of directors.
Joseph J. Farnan, Jr. Joins CTD Holdings Board of Directors
Marketwired - Wed Nov 04, 11:31AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that Judge Joseph J. Farnan of the Wilmington, Delaware law firm, Farnan LLP, has joined its Board of Directors.
CTD Holdings appoints two new co-chairs to SAB
M2 - Tue Oct 27, 5:08AM CDT
Biotechnology company CTD Holdings (Other OTC:CTDH) disclosed on Monday that it has appointed Dr Rita Colwell and Dr Sharon Hrynkow as co chairs of its Scientific Advisory Board (SAB).
CTD Holdings Names Dr. Rita Colwell and Dr. Sharon Hrynkow Co-Chairs of Scientific Advisory Board
Marketwired - Mon Oct 26, 11:40AM CDT
CTD Holdings, Inc. (OTCQB: CTDH) today announced Dr. Rita Colwell, Distinguished University Professor, University of Maryland at College Park and Johns Hopkins University Bloomberg School of Public Health, has joined their Scientific Advisory Board (SAB) and will co-chair the SAB with Dr. Sharon Hrynkow, Senior Vice President for Medical Affairs, CTD.
N. Scott Fine Named CEO of CTD Holdings
Marketwired - Wed Sep 16, 2:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that the Board of Directors has named N. Scott Fine as Chief Executive Officer. Mr. Fine, who was previously Chairman of the Board and Lead Director, will continue as Chairman. Director Markus W. Sieger was named Lead Director, and Senior Medical Advisor Dr. Sharon H. Hrynkow joins the company as Senior Vice President for Medical Affairs.
CTD Holdings to Present at UK Annual Conference for NPC Patients, Families and Caregivers
Marketwired - Thu Sep 03, 6:00AM CDT
September 3, 2015 - CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, will make a formal presentation on progress in its clinical trials program on September 19 at a major annual meeting of caregivers and families struggling with Niemann-Pick Type C (NPC) disease. The meeting will be convened in Bedfordshire, England, under the auspices of the Niemann-Pick UK, a registered charity in the United Kingdom. The annual meeting brings together experts from around the world for interactive sessions on clinical and practical management of NPC, and on clinical trials aimed at slowing the progression of the disease. The company's formal presentation will be held on Saturday, September 19.
CTD Holdings announces private placement of 1.3m shares of its common stock
M2 - Tue Sep 01, 10:45AM CDT
Biotechnology company CTD Holdings (Other OTC:CTDH) said on Monday that it has completed the sale of 1,300,000 shares of its common stock at a price per share of USD0.50 in a private placement.
CTD Holdings Sets Meeting With European Health Authority on Clinical Development Plans
Marketwired - Mon Aug 24, 6:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that is developing Trappsol® Cyclo(TM) as a treatment for Niemann-Pick Type C (NPC) disease, today announced that the company has set a meeting with a European health authority to discuss its initial clinical development plans. These plans have been based upon extensive discussions with clinical experts, some of whom have more than five years of experience from the compassionate use of Trappsol® Cyclo(TM) in the management of NPC patients.
